Antigen-specific regulatory T cells (Tregs) possess the potential to reduce excess immune responses in autoimmune diseases, allergy, rejection after organ transplantation and graft-versushost disease (GVHD) following hematopoietic stem cell transplantation. Although in vitro-expanded antigen-specific induced Tregs (iTregs) have been considered to be a promising therapeutic agent against such excessive immune reactions, the instability of iTregs after transfer is a fundamental problem in their clinical application. In this study, we searched for the optimal way to generate stable iTregs for the prevention of the murine GVHD model, in which conventional iTregs are reported to be inefficient. Allo-antigen-specific iTregs were generated by co-culturing naive T cells with allogenic dendritic cells in the presence of TGF-β and retinoic acid. By examining various agents and genes, we found that vitamin C stabilized Foxp3 expression most effectively in adoptively transferred iTregs under a GVHD environment. Vitamin C treatment caused active DNA demethylation specifically on the conserved non-coding sequence 2 (CNS2) enhancer of the Foxp3 gene locus in allo-antigenspecific iTregs and reduced iTreg conversion into pathogenic exFoxp3 cells. Vitamin C-treated iTregs suppressed GVHD symptoms more efficiently than untreated iTregs. Vitamin C also facilitated induction of a FOXP3 high iTreg population from human naive T cells, which was very stable even in the presence of IL-6 in vitro. The treatment of vitamin C for iTreg promises innovative clinical application for adoptive Treg immunotherapy.
Introduction
Graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality following allogenic hematopoietic stem cell transplantation (HSCT), despite decades of research and trials in post-transplant immunosuppressive therapies (1) . GVHD is initiated by the presentation of alloantigens by host antigen-presenting cells to donor CD4 + and CD8 + T cells; thereafter donor T cells expand and become alloreactive effector T cells (2) . The alloreactive T cells then induce tissue injury and dysfunction through the production of inflammatory cytokines and cytotoxicity (3, 4) . Regulatory T cells (Tregs) play essential roles in immunological tolerance and suppress excess immune responses. Tregs are specified by the expression of Foxp3, which is essential for the differentiation, maintenance and function of Tregs. Tregs include thymus-derived Tregs (tTregs) and induced Tregs (iTregs), which are generated from naive CD4 + T cells in vitro by the TCR stimulation in the presence of TGF-β (5) .
Induction of tolerance by antigen-specific Tregs has long been considered a promising therapeutic strategy to prevent GVHD following HSCT (6) . Umbilical cord blood tTregs have been used for clinical trials to treat GVHD following allogeneic HSCT, and they showed safety and clinical efficacy in reducing the risk of GVHD (7) . However, due to the low tTreg content in the blood, generating stable antigenspecific iTregs in vitro has been considered to be a feasible approach (8) .
Unlike tTregs, however, iTregs are unstable, which has been a fundamental difference between the two types of cells. It has been shown that the transfer of tTregs, but not iTregs, partly ameliorated GVHD in murine models (9, 10) . This could be due to unstable Foxp3 expression in iTregs. iTregs have been shown to convert into pathogenic exFoxp3 cells after losing Foxp3 expression (5) . The tTreg-specific demethylated regions (TSDRs) have been shown to be distributed in genes that are known to be important for Treg differentiation and function. Among TSDRs, the unstable expression of Foxp3 in iTregs is associated with the dense methylation of the 'conserved non-coding sequence-2' (CNS2) enhancer region of the Foxp3 locus (11) . TSDR demethylation is probably achieved through active reactions mediated by ten-eleven-translocation (Tet) family proteins, which mediate stepwise oxidization of 5-methylcytosine (5mC) into 5-carboxylcytosine (5caC).
Currently, several agents have been shown to improve the stability of Foxp3 expression. For example, all-trans retinoic acid (ATRA), the active derivative of vitamin A, and rapamycin, efficiently induce Foxp3 expression in the presence of TGF-β, resulting in the generation of highly suppressive iTregs with sustained stability (12, 13) . Sustained IL-2 signals sent by an IL-2-anti-IL-2 antibody complex induced CNS2 demethylation in iTregs and stabilized Foxp3 expression (14) . Recently, overexpression of the TET catalytic domain (15, 16) or treatment with vitamin C and hydrogen sulfide have been shown to stabilize Foxp3 expression by promoting Tet-mediated DNA demethylation of the Foxp3 locus (17) (18) (19) . iTregs generated in the presence of vitamin C are more stable and efficiently suppress murine colitis models (17) . Collectively, the combination of Foxp3-inducing agents and stabilizing agents is expected to improve the stability of Foxp3 expression in iTregs.
In this study, we have sought for the most efficient method to generate stable allo-antigen-specific iTregs for the prevention of disease in a murine model of acute GVHD. By examining various sort of gene transductions and agents, we found that the combination of ATRA and vitamin C was the most effective at generating stable allo-antigen-specific iTregs among those we examined, and we confirmed its clinical efficacy to ameliorate GVHD in mice. We also confirmed that vitamin C induced a stable Foxp3 high population in human iTregs. We propose that this strategy has the potential to be used in a clinical application for the generation of antigenspecific stable iTregs and Treg therapy for GVHD and autoimmune diseases.
Methods

Mice
We purchased 6-to 8-week-old male BALB/c AJc1 mice from Tokyo Laboratory Animals Science Co. Ltd (Tokyo, Japan). Foxp3 hCD2-hCD52 (C57BL/6 genetic background) mice were kindly provided from the laboratory of Dr. S. Hori (The University of Tokyo, Tokyo, Japan). Mice were kept in conventional conditions in Keio University (Tokyo, Japan). All experiments using these mice were approved by the Institutional Animal Care and Use Committee (IACUC) (approved number 08004) of Keio University and performed according to the guidelines of IACUC. All experiments using these mice were also approved by and performed according to the guidelines of the Animal Ethics Committee of Keio University.
Antibodies and reagents
For the flow cytometry analysis, FITC, PE, peridinin chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5), allophycocyanin (APC), PE-Cy7 and APC-Cy7-conjugated antibodies were purchased from BioLegend (San Diego, CA, USA) or eBioscience (San Diego, CA, USA). The following clones were used: anti-mouse CD4 (RM4-5), anti-mouse CD45.1 (A20), antimouse H-2K b (AF6-88.5), anti-mouse TCRβ (H57-597), antimouse CD103 (2E7), anti-mouse CD25 (PC61.5), anti-mouse Thy1.1 (HIS51), anti-mouse Foxp3 (FJK16s), anti-mouse CTLA-4 (UC10-4F10-11), anti-mouse IFN-γ, (XMG1.2), antimouse IL-21 (mhalx21), anti-human CD2 (RPA2.10), antihuman CD4 (RPA-T4), anti-human CD25 (BC96), anti-human CD45RA (HI100), anti-human CD127 (A019D5), anti-human CCR7 (G043H7) and anti-human FOXP3 (236A/E7). Fixable Viability Dye eFluor 780 (FVD780) was used to remove dead cells. Murine IL-2, human IL-2, human IL-4, human IL-6 and human GM-CSF were purchased from Peprotech (Rocky Hill, NJ, USA); murine GM-CSF was purchased from Wako Pure Chemical Industries (Osaka, Japan); and human TGF-β1, anti-human IFN-γ antibody (B27) and anti-human IL-4 antibody (8D4-8), HumanTrustain TCX ™ were purchased from BioLegend. ATRA, 5-aza-2′-deoxytidine (5-aza-dC) and l-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (vitamin C) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Belinostat was purchased from Chemscene LLC (Monmouth Junction, NJ, USA). Normal human male serum was purchased from Innovative Research Inc (Novi, MI, USA).
GVHD induction and prevention
BALB/c host male mice (H-2K d CD45.2 + ) were conditioned by myeloablative total body irradiation using a Faxitron X-ray system (Faxitron, Tucson, AZ, USA) at a dose of 8.0 Gy, split into two doses separated by at least 3 h. Within 4 h after irradiation, sex-and age-matched 5 × 10 6 B6.Ly5.1 (H-2K b CD45.1 + ) bone marrow (BM) cells with 1 × 10 6 CD25 + cell-depleted conventional T cells isolated using magneticactivated cell sorting (MACS) from the spleen were injected via the tail vein in an SFO3 medium (Iwai Chemical, Tokyo, Japan). Usually, iTregs were transferred intravenously together with conventional T cells (1 × 10 6 cells) and BM cells (5 × 10 6 cells) into lethally irradiated BALB/c recipients. Mice were sacrificed and analyzed by flow cytometry on day 6-8 after bone marrow transplantation (BMT). Tissue sections were stained with H&E. In situ TUNEL assay was performed according to the manufacturer's instructions using the In Situ Cell Death Detection Kit, POD (Roche Diagnostics, Basel, Switzerland).
Flow cytometry
For intracellular cytokine analysis, cells were stimulated with 50 ng ml −1 PMA, 1 µg ml −1 ionomycin and brefeldin A solution for 4-5 h at 37°C. For intracellular staining, anti-mouse Foxp3, anti-mouse IFN-γ, anti-mouse IL-21, anti-mouse CTLA-4 and anti-human FOXP3 were stained using fixation and permeabilization buffer (eBioscience). Data were acquired through FACS Canto II or Aria II (BD Bioscience, Franklin Lakes, NJ, USA) and were analyzed with Flowjo software (Tree Star, Ashland, OR, USA).
Preparation of bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells (BMDCs) were prepared as described previously (20) . Briefly, BM cells harvested from the BALB/c AJc1 femurs and tibia were cultured in 24-well plates (1 × 10 6 per well) with 10 ng ml −1 murine GM-CSF in complete medium RPMI 1640 (Invitrogen, Carlesbad, CA, USA) supplemented with 10% fetal bovine serum, 0.2% penicillin/streptomycin, 0.05 mM 2-mercaptoethanol (ME), 100 nM nonessential amino acids, 2 mM l-glutamine. At day 3 and 5, all the media were changed and cells were used for co-culture on day 6-7.
In vitro induction of murine iTregs
CD4
+ T cells were isolated using AutoMACS pro (Miltenyi Biotec, Bergisch Gladbach, Germany) with biotin-conjugated antibodies against mouse B220 (RA3-6B2), mouse CD8α (53-67), mouse CD49b (DX-5), mouse CD11b (M1/70), mouse CD11c (N418), mouse CD25 (PC61), mouse TER119 (TER-119), mouse Ly6G (RB6-8C5) and human CD2 (RPA2.10) (BioLegend or eBioscience) from the spleen and lymph nodes (LNs) of 6-to 8-week-old male Foxp3 hCD2 mice. ) and ATRA (10 nM) in the presence or absence of vitamin C (100 µg ml −1 ). On day 4, half of the medium was changed. Cells were harvested on day 6-7 and incubated with Fc-blocker, then labeled with anti-mouse CD4 and anti-human CD2 antibodies, and the CD4 + human CD2 + cells were then sorted using FACS Aria II. The Treg purity was >95% based on anti-Foxp3 antibody staining. For antigennon-specific in vitro iTregs, isolated naive CD4 + T cells (5 × 10 5 cells) were cultured on 24-well plates under iTreg conditions using anti-CD3ε (plate-coated 2C11, 4 µg ml ) and murine IL-2 (10 ng ml −1 ).
Preparation of human monocyte-derived dendritic cells
Human peripheral blood mononuclear cells (PBMCs) provided by healthy donors were prepared by specific gravity centrifugal methods. We positively selected CD14 + monocytes from PBMCs using human CD14 microbeads (#130-050-201) and a Quadro MACS separator (Miltenyi Biotec). CD14 + monocytes were cultured in six-well plates (1 × 10 6 per well) with 20 ng ml −1 human IL-4 and 50 ng ml −1 human GM-CSF in complete medium RPMI 1640 supplemented with 10% normal human male serum, 0.2% penicillin/streptomycin, 0.05 mM 2-ME, 100 nM nonessential amino acids, 2 mM l-glutamine, 0.01 M HEPES and 1 mM pyruvate. At day 3 and 6, half of the media was changed and cells were used for co-culture on day 8.
In vitro induction of human iTregs
We prepared CD4 + T cells from PBMCs provided by three healthy male donors with depletion of non-CD4 + T cells through a human CD4 + T-cell isolation kit (#130-096-533, Miltenyi Biotec) and Quadro MACS separator. Isolated CD4 + T cells were stained with fluorophore-conjugated anti-CD4, CD25, CD45RA, CD127, CCR7 antibodies and naive CD4 + T cells were purified by gating on CD4
hi cells using a cell sorter. The purity of naive T cells was >99%. For allo-antigen-specific in vitro iTreg generation, purified naive T cells (5 × 10 4 per well) were co-cultured with 20 Gy irradiated-allo-monocyte-derived dendritic cells (MDDCs) (5 × 10 3 per well), using 96-well U-bottom plates in a complete medium with anti-human IFN-γ antibody (2 µg ml ). On day 4, half of the medium was changed and IL-2 were appended to 100 ng ml 
Retroviral transduction
The retroviruses carrying cDNAs for Smad3, Stat5b-CA (constitutive active form), Foxo1-CA, NFAT-CA and Nr4a2 were prepared as described previously (22) (23) (24) (25) . Briefly, 293T cells were transiently transfected with plasmid constructions and retroviral helper vectors. Supernatant was collected in 48 h. Virus-containing solutions were added to the cells on day 4 under iTreg culture conditions in the presence of polybrene (4 µg ml −1 ), followed by centrifugation at 2500 rpm for 2 h at 35°C. Retrovirus-transduced cells were isolated by FACS sorting as GFP-or Thy1.1-positive cells and then transferred to recipient mice.
Bisulfite sequencing
Cells were lysed using Wizard SV Lysis Buffer (Promega, Madison, WI, USA). Genomic DNAs were isolated by phenol-chloroform extraction, isopropanol precipitation and 70% ethanol purification. Genomic DNAs were digested with BamHI, and the same amount of digested Prevention of GVHD by stabilized iTregs 459 DNA (<1.5 µg) was aligned to 19 µl by adding H 2 O. Next, 1.2 µl of 5 M NaOH was added and incubated at 37°C for 15 min. Then, 121.2 µl of bisulfite mixture was added and incubated for 1 h at 80°C. The bisulfite mixture (121.2 µl) consisted of 3.6 M sodium bisulfite (1.92 g in 4.4 ml H 2 O; 107 µl), 0.57 mM hydroquinone (11 mg in 10 ml H 2 O; 7 µl) and 0.3 M NaOH (5 M NaOH; 7.2 µl). After purification and extraction using a 50 µl GP3 solution from a column employing a FastGene Gel/PCR Extraction Kit (Nippon Genetics, Tokyo, Japan), 3 µl of 5 M NaOH was added and incubated for 5 min at 37°C to complete the bisulfite reaction. Bisulfite products were precipitated using isopropanol with 10 µg glycogen and rinsed using 70% ethanol. The target locus was amplified by Quick Taq HS DyeMix (TOYOBO Life Science, Osaka, Japan) polymerase with a bisulfite sequence primer designed by MethPrimer [online] (murine Foxp3 CNS2 forward primer: TTTTGGGTTTTTTTGGTATTTAAGA and reverse primer: AACTAACCAACCAACTTCCTACACTAT; murine IFN-γ CNS1 forward primer: AGTATTTATTTATATTGAGTGG and reverse primer: TTTCAACAATATCTCTATAAACCC; human FOXP3 CNS2 forward primer: TTGGGTTAAGTTTGTTGTAGGATAG and reverse primer: ATCTAAACCCTATTATCACAACCCC), and the PCR products were cloned into the pGEM-T EASY Vector (Promega). Plasmids were purified and sequenced using SP6 primer. Methylation analysis was performed using the quantification tool for methylation analysis.
ChIP assay
A ChIP assay for various transcription factors was performed as described previously (22) . Briefly, iTregs were isolated using MACS with anti-biotin hCD2 antibody and anti-biotin beads, and then fixed with 1% formaldehyde at room temperature for 60 min before being suspended in an SDS lysis buffer. After sonication by the S220 Focusedultrasonicator (Covaris Inc., Woburn, MA, USA), samples were incubated with 2 µg antibodies or control IgG for 4 h at 4°C. After the addition of Dynabeads protein G (Life Technologies, Carlsbad, CA, USA), the immunoprecipitates were sequentially washed once each with a low-salt buffer, a high-salt buffer and a LiCl buffer and twice with a TE buffer. The DNA-protein complex was eluted by heating at 65°C overnight. Proteins were then digested with proteinase K. DNA was recovered using the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany) and then subjected to real-time PCR analysis.
Statistical analyses
Data are presented as means ± SD, unless otherwise stated. Statistical significance was determined by Tukey's multiple comparison test. The two-tailed Student's t-test was used for experiments with two groups. P values were represented as follows: ***P < 0.001, **P < 0.01, *P < 0.05. P value >0.05 was considered to not be statistically significant (NS). Survival was estimated and plotted using Kaplan-Meier methods, and the difference between subgroups was estimated using logrank methods.
Results
Screening of Foxp3-stabilizing genes and agents for iTregs in a murine GVHD model
We established a major MHC-mismatched GVHD model by transferring CD45. (Fig. 1A) . In this model, recipient mice usually die within 7-10 days after BMT because of severe acute GVHD. Allo-antigenspecific iTregs were generated by co-culturing naive T cells from We tested a panel of pharmacological agents and gene transduction during co-culture for their effects on iTreg stability, with flow cytometry analysis on day 6-8 after BMT (Fig. 1A) .
First, we tried the overexpression of transcription factors such as Smad3, Stat5b-CA (constitutive active form), Foxo1-CA, NFAT-CA and Nr4a2, which are known to be associated with Treg induction under control of the TCR, IL-2 and TGF-β, and then promote differentiation of iTregs (26, 27) . Each of these transcription factors binds to the regions of the promoter and enhancer of Foxp3 and has been reported to contribute to the expression of Foxp3 (23) (24) (25) 28) . For example, Smad2 and Smad3 were shown to be essential for Foxp3 induction by TGF-β (29) . Although Smad3 was shown to activate Foxp3 expression in vitro (24), Foxp3 retention was not so drastically improved in Smad3-transduced iTreg cells in GVHD model mice (Fig. 1B) . Foxo1-CA was reported to up-regulate Foxp3 expression (30); however, we did not see any effects on Foxp3 stability in the in vivo GVHD model (Fig. 1C) . Although NFAT and STAT5 slightly increased Foxp3 stability, none of the transcription factors we examined was very effective at improving Foxp3 stability in iTregs in vivo (Fig. 1B and C) .
We then examined the effect of epigenetic modifiers, histone deacetylase inhibitor (HDACi), 5-aza-2′-deoxycytidine (5-aza-dC) and vitamin C, on stability of Foxp3 expression in iTregs. 5-aza-dC and HDACi administration were reported to ameliorate acute GVHD in the murine model (31, 32) . Belinostat, an HDAC inhibitor (33), was not effective for improving Foxp3 stability (Fig. 1B and C) although it promoted acetylation in histones (H3) of Foxp3 promoters, Foxp3 CNS1 and Foxp3 CNS2 (Supplementary Figure S1 , available at International Immunology Online), without significant T-cell toxicity. We then confirmed that 5-aza-dC, an inhibitor of DNA methylation that has been reported to stabilize Foxp3 expression in iTregs (30) , induced DNA demethylation of Foxp3 CNS2; however, it was also found to accelerate demethylation of the CNS1 enhancer region of the inflammatory cytokine Ifng locus, even in an iTreg conditioning culture (Supplementary Figure S2 , available at International Immunology Online). Additionally, 5-aza-dC showed substantial cytotoxicity in coculture, which was considered to be another caveat for the clinical application of this chemical. Next, we demonstrated the effects of vitamin C, which is known to enhance the demethylating activity of Tet enzymes (17) . We eventually found that only vitamin C effectively improved Foxp3 expression maintenance (90%, vitamin C-treated iTregs versus 40-60%, vehicle-treated iTregs) (Fig. 1C) . Collectively, among the panel of gene transductions and reagents, only vitamin C showed positive effects on iTreg stability in the murine acute GVHD model. Thus, we decided to investigate the molecular mechanisms of this agent on iTreg stabilization, as well as its effects on treatment of GVHD.
Vitamin C caused active demethylation of TSDRs in iTregs
CD4
+ naive T cells were co-cultured with allogenic DCs for 6-7 days in iTreg conditions (see 'Methods' for details) with vitamin C (100 µg ml −1 ) or vehicle. Foxp3 expression of vitamin C-treated iTregs was slightly higher compared with control iTregs (Fig. 2A) . In contrast to the effects of 5-aza-dC, vitamin C rather increased proliferation and/or survival of T cells, thus improved the recovery of Foxp3 + cells (Fig. 2B ). The markers of iTregs such as CD25, CD103 and CTLA-4 expression were almost equivalent between vitamin C-treated iTregs and vehicle-treated iTregs (Fig. 2C ).
As vitamin C is an agent which enhances locus-specific DNA demethylation by Tet enzymes, and DNA methylation/ demethylation critically regulate Treg cell stability and function, we next investigated the effects of vitamin C treatment on the methylation status of iTreg cells. male mice. The CNS2 region in naive T cells was densely methylated, whereas that in tTregs was highly demethylated, as previously reported (11) . In iTreg cells, vitamin C facilitated DNA demethylation of the Foxp3 CNS2, showing the extent of demethylation to the level equivalent to that of tTregs. Furthermore, vitamin C-mediated demethylation was extended to other Treg cell-specific regulatory lesions such as Ikzf4 and Ctla4 (Fig. 3) . On the other hand, the same regions of vehicle-treated iTregs remained to be methylated similarly to those of naive T cells. Importantly, in contrast to the relatively non-specific demethylation effects shown by 5-aza-dC at the Ifng CNS1 enhancer, this locus was found to be kept methylated in vitamin C-treated iTregs (Supplementary Figure  S3 , available at International Immunology Online). These data indicate that vitamin C treatment accelerates demethylation of TSDRs, while keeping methylation of the effector cytokine gene locus, i.e. the Ifng CNS1 enhancer.
Vitamin C-treated iTregs stabilized Foxp3 expression and suppressed the acute GVHD
To evaluate iTreg stability induced by vitamin C treatment, we next intravenously transferred vitamin C-treated or control iTregs (1 × 10 6 cells) with conventional T cells (1 × 10 6 cells) and BM cells into allogenic recipients. Seven days after BMT, we evaluated iTreg stability by flow cytometry analysis (Fig. 1A) . Vitamin C treatment effectively improved Foxp3 maintenance compared with control iTregs in the GVHD model (Fig. 4A) . IFN-γ and IL-21 have been implicated in the pathology of GVHD (34) (35) (36) . Production of these inflammatory cytokines was observed in control iTregs that lost Foxp3 expression (exFoxp3) but was far less observed in their vitamin C-treated counterparts ( Fig.  4B and C) . Finally, to assess the therapeutic effects of vitamin C-treated iTregs, we adoptively transferred vitamin 
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C-treated iTregs into GVHD in mice. Vitamin C-treated iTregs prolonged survival time compared with vehicletreated iTregs (Fig. 5A ). Inflammation associated with GVHD shortens the colon length. Amelioration of acute GVHD by vitamin C-treated iTregs was also confirmed by colon length on day 7 after BMT ( Fig. 5B) . Histological evaluation of the small intestine and colon showed reduction in accumulation of inflammatory cells, destruction of epithelium in mice that received vitamin C-treated iTregs compared with mice that received vehicle-treated iTregs 6 cells) and BM cells (5 × 10 6 cells) into lethally irradiated BALB/c recipients, and animal survival was followed over time. Survival time was estimated and plotted using Kaplan-Meier methods, and the difference between subgroups was estimated using log-rank methods. Data are combined from three independent experiments (n = 7 in no iTreg group, n = 9 in vehicle-treated iTreg group, and n = 8 in vitamin C-treated iTreg group). (B) On day 7 after BMT, mice were sacrificed and colon length was measured (n = 3 per group). **P < 0.01, * P < 0.05. (C, D) Control or vitamin C-treated iTregs (3 × 10 5 ) were transferred into irradiated recipient mice together with 5 × 10 6 BM cells and 1 × 10 6 effector T cells. Seven days after BMT, mice from each group were sacrificed, and samples of the small intestine and colon were analyzed by H&E staining (C) or TUNEL assay (D). In (C), arrows indicate crypt cell apoptosis (black arrow head), crypt abscess (white arrow head) and focal crypt destruction (white arrow). Scale bars: 100 µm. In (D), cell nucleus are stained with DAPI and apoptotic cells were stained with TUNEL. Scale bars, 50 µm. Quantitative counting of TUNEL-positive cells are shown in the right panel.
or no iTregs (Fig. 5C) . The TUNEL assay also revealed that apoptotic cell death of epithelial cells was reduced more efficiently by vitamin C-treated iTregs compared with control iTregs (Fig. 5D ).
Vitamin C facilitates induction of stable human iTregs
To obtain human allo-antigen-specific iTregs, human CD4 + naive T cells were co-cultured with allogenic MDDCs for 7 days under iTreg conditions (TGF-β1, IL-2 and ATRA) in the presence or absence of vitamin C (100 µg ml −1 ). As shown in Fig. 6(A) + fraction (Fig.  6B) ], but not in the absence of vitamin C. To examine the stability of this FOXP3 hi iTreg fraction, iTregs were further cultured for an additional 7 days in the presence or absence of IL-2 or IL-6 without TGF-β1, which mimics an inflammatory condition. The FOXP3 hi fraction in vitamin C-treated iTregs was stable for at least 7 days even in the presence of IL-6 (Fig. 6C) , suggesting that vitamin C-induced FOXP3 hi iTregs were very stable. We next investigated the effects of vitamin C treatment on the methylation status of the human FOXP3 CNS2 region which contains 11 CpG sites (21) . The CNS2 region in naive T cells was completely methylated, whereas that in tTregs was highly demethylated, as previously reported (37). Since we do not have a method to separate the FOXP3 hi fraction from the entire FOXP3 + population, we performed bisulfate sequencing using the CD25 + fraction of iTregs. The FOXP3 CNS2 was completely methylated in the CD25 + fraction of vehicle-treated iTregs, while partial DNA demethylation (~12%) of CNS2 was observed in vitamin C-treated iTregs (Fig. 6D) . This may be due to the limited fraction (~40%) of FOXP3 hi iTregs in CD25 + cells. These results support our hypothesis that vitamin C facilitates DNA demethylation of CNS2 not only in murine but also in human allo-antigen-specific iTregs.
Discussion
Although antigen-specific in vitro-expanded Tregs (iTregs) have been considered a promising therapeutic agent for alloimmune reactions such as GVHD, accumulating evidence has suggested that iTregs easily lose their characteristics with quick cessation of Foxp3 expression (13) . In order to overcome the problem, we investigated the optimum methods to generate stable iTregs for the prevention of disease in a murine model of acute GVHD, and we found that vitamin C treatment is the most effective and convenient way to generate stable iTregs, which is applicable to inducing tolerance to the murine GVHD model. Previously, we reported that combination of vitamin C and low oxygen (5% O 2 ) facilitates DNA demethylation of the CNS2 (15) . However, we noticed that low oxygen conditions reduced Foxp3 levels in iTregs, probably because of various effects of hypoxia on DCs (38) . Thus, we did not use low oxygen condition in this study. We found that vitamin C treatment induced DNA demethylation of the Foxp3 CNS2 and was extended to other TSDRs such as Ikzf4 and Ctla4, although demethylation of Tnfrsf18 was not as efficient as other TSDRs, which is nearly consistent with the findings of a previous report (18) . We noticed that CNS1 of the Ifng locus was not demethylated by vitamin C, where DNA demethylation plays a role in the expression of Ifng (39) . It has been shown that Tet2-mediated demethylation was specifically detected at gene loci which encode lineage-specifying transcription factors as well as effector cytokines in T h 1 and T h 17 subsets (e.g. at Tbx21 and Ifng loci in T h 1 cells and the Foxp3 CNS2 region in Tregs) (40) . As methylation of the Ifng CNS1 region inversely correlates with Ifng gene expression, this TSDR-specific demethylation is preferable for the generation of iTregs expressing stable Foxp3 without affecting other inflammatory gene expression. These results suggest that the activity of Tet enzymes is only restricted to the necessary gene loci in the corresponding CD4 + T-cell subsets. The tolerance induction mechanism by antigen-specific iTregs in the murine GVHD model remains to be clarified. Previously, we showed the increase of tolerogenic DCs and CTLA4 + CD8
+ T cells in the heart transplantation model with iTreg transfer (41) . Since transferred iTregs were undetectable 2-3 weeks after transfer (data not shown), such an 'infectious tolerance' mechanism is likely to be the mechanism for the maintenance of tolerance several weeks after BM transfer (42) . However, we did not find such an increase in the tolerogenic DCs and CD8 + T cells in GVHD model mice transferred with vitamin C-treated iTregs (Supplementary Figure S4 , available at International Immunology Online). Since iTregs must be transferred at the same time with allogenic T cells in the GVHD mice, we suspected that iTregs suppress activation of allospecific T cells by IL-10, TGF-β and other mechanisms. Alternatively, conversion to pathogenic T cells (exFoxp3 cells) from iTregs may be modified by vitamin C treatment. We found that the production of inflammatory T-cell cytokines such as IFN-γ and IL-21 that was observed in exFoxp3 cells from untreated iTregs was little found in the case of vitamin C-treated iTregs. Thus, such a low frequency of the conversion to exFoxp3 cells by vitamin C treatment may contribute to the induction of long-term tolerance by stable iTregs. Further study is necessary to define the mechanism of tolerance induction in the GVHD model by Tregs.
The reason for the failure of generating stable iTregs by the gene transfer also remains to be clarified. Previous reports suggested that those genes such as Smad3, Nr4a2, an active form of STAT5 and Foxo1 enhance Foxp3 expression at high levels (22, 23, 25, 43, 44) . Those conclusions were mostly obtained in vitro. The cytokine storm in the in vivo GVHD model may be too severe to maintain Foxp3 expression. Another possibility is that transduction of a single transcription factor is not enough for the long-term maintenance of Treg cells in vivo. It has been reported that combinatorial transduction of STAT5-CA and Foxo1-CA showed an additive effect in restoring Foxp3 expression under an inflammatory setting in vivo (23) . Nevertheless, our results clearly indicate that the ability of transcription factors for the maintenance and/or induction of Foxp3 expression should be evaluated not only in vitro, but also in vivo.
A few clinical trials for the Treg-mediated induction of tolerance in organ transplantation were reported. Adoptive transfer of an ex vivo-expanded Treg-enriched cell product was conducted in 10 patients shortly after liver transplantation (45) . In these cases, cells were generated using a 2-week co-culture of recipient lymphocytes with irradiated donor cells in the presence of anti-CD80/86 monoclonal antibodies. Recently, an in vitro expansion protocol for manufacturing large numbers of umbilical cord blood-derived Tregs has been reported for the prevention of human GVHD in allogeneic HSCT patients (46) .
Those clinical trials utilized antigen-non-specific thymicderived Tregs. To extend clinical application of antigen-specific iTregs in humans, we tried to generate allo-antigen-specific stable iTregs from human PBMC-derived naive T cells with vitamin C. Previous reports suggest that the combination of ATRA and rapamycin is the most effective way to induce FOXP3 high iTregs from human naive CD4 + T cells (47) . In our study, vitamin C facilitated induction of more stable and FOXP3 extremely high iTregs in human (Fig. 6) . However, the results of bisulfite sequences showed that demethylation in the FOXP3 CNS2 region in vitamin C-treated human iTregs was only partial (~12%). This may be because only 40% of 'genuine' iTregs with FOXP3 hi were included in our CD25 + fraction. It is necessary to find markers to separate FOXP3 hi stable iTregs from FOXP3 low 'pseudo' Tregs. Such markers are also necessary to apply human iTregs for adoptive T-cell therapy, since the functions and stability of FOXP3 low Tregs after transfer to the human body are not known. Our vitamin C-treated human iTregs will be useful to find such markers.
In summary, vitamin C stabilized Foxp3 expression with specific DNA demethylation of the Foxp3 CNS2 as well as Treg-associated genes in antigen-specific iTregs, preventing them from conversion into inflammatory exFoxp3 cells, thus ameliorating the pathogenesis of a murine model of GVHD. Our findings suggest the potential of the clinical application of Treg therapy combined with vitamin C treatment for GVHD and autoimmune diseases.
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